AR069803A1 - 5- anilinoimiazopiridinas y metodos de uso - Google Patents
5- anilinoimiazopiridinas y metodos de usoInfo
- Publication number
- AR069803A1 AR069803A1 ARP080105524A ARP080105524A AR069803A1 AR 069803 A1 AR069803 A1 AR 069803A1 AR P080105524 A ARP080105524 A AR P080105524A AR P080105524 A ARP080105524 A AR P080105524A AR 069803 A1 AR069803 A1 AR 069803A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cr14r15
- cr19r20
- nhc
- carbocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Devices For Indicating Variable Information By Combining Individual Elements (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a imidazopiridinas de formula 1 con actividad anticancerígena y/o antiinflamatoria y, más específicamente, a imidazopiridinas las cuales inhiben la actividad de MEK quinasa. Proporciona composiciones y métodos utiles para inhibir el crecimiento celular anormal o para tratar un trastorno hiperproliferativo, o para tratar una enfermedad inflamatoria en un mamífero, también se refiere a métodos para utilizar los compuestos para el diagnostico in vitro, in situ, e in vivo o tratamiento de células de mamífero, o afecciones patologicas asociadas. Reivindicacion 1: Un compuesto de formula 1 y sus sales, donde: Z1 es CR1 o N; R1 es H, alquilo C1-3, halo, CF3, CHF2, CN, ORA o NRARA; R1' es H, alquilo C1-C3, halo, CF3, CHF2, CN, ORA, o NRARA; donde cada RA es independientemente H o alquilo C1-3; Z2 es CR2 o N; Z3 es CR3 o N; siempre que solamente uno de Z1, Z2 y Z3 pueda ser N al mismo tiempo; R2 y R3 se seleccionan, con independencia, entre H, halo, CN, CF3, -OCF3, -NO2, -(CR14R15)nC(=Y')R11, -(CR14R15)nC(=Y')OR11, -(CR14R15)nC(=Y')NR11R12, (CR14R15)nNR11R12, -(CR14R15)nOR11, -(CR14R15)nSR11, -(CR14R15)nNR12C(=Y')R11, -(CR14R15)nNR12C(=Y')OR11, -(CR14R15)nNR13C(=Y')NR11R12, -(CR14R15)nNR12SO2R11, -(CR14R15)nOC(=Y')R11, -(CR14R15)nOC(=Y')OR11, -(CR14R15)nOC(=Y')NR11R12, -(CR14R15)nOS(O)2(OR11), -(CR14R15)nOP(=Y')(OR11)(OR12), -(CR14R15)nOP(OR11)(OR12), -(CR14R15)nS(O)R11, -(CR14R15)nS(O)2R11, -(CR14R15)nS(O)2NR11R12, -(CR14R15)nS(O)(OR11), -(CR14R15)nS(O)2(OR11), -(CR14R15)nSC(Y')R11, -(CR14R15)nSC(=Y')OR11, -(CR14R15)nSC(=Y')NR11R12, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo, heterociclilo, arilo, y heteroarilo; R4 es H, alquilo C1-6 o carbociclilo C3-4; Y es W-C(O)- o W'; W X1-N(R5)- o -R11'-O-; R5 es H o alquilo C1-12; X1 se selecciona entre R11' y -OR11; cuando X1 es R11', X1 se toma opcionalmente junto con R5 y el átomo de nitrogeno al cual están unidos para formar un anillo saturado o insaturado de 4-7 miembros que tiene 0-2 heteroátomos adicionales seleccionados entre O, S y N, donde dicho anillo está opcionalmente sustituido con uno o más grupos seleccionados entre halo, CN, CF3, -OCF3, -NO2, oxo, -(CR19R20)nC(=Y')R16, -(CR19R20)nC(=Y')OR16, -(CR19R20)nC(=Y')NR16R17, -(CR19R20)nNR16R17, -(CR19R20)nOR16, -(CR19R20)n-SR16, -(CR19R20)nNR16C(=Y')R17, -(CR19R20)nNR16C(Y')OR17, -(CR19R20)nNR18C(=Y')NR16R17, -(CR19R20)nNR17SO2R16, -(CR19R20)nOC(=Y')R16, -(CR19R20)nOC(=Y')OR16, -(CR19R20)OC(=Y')NR16R17, -(CR19R20)nOS(O)2(OR16), -(CR19R20)nOP(=Y')(OR16)(OR17), -(CR19R20)nOP(OR16)(OR17), -(CR19R20)nS(O)R16, -(CR19R20)nS(O)2R16, -(CR19R20)nS(O)2NR16R17, -(CR19R20)nS(O)(OR16), -(CR19R20)nS(O)2(OR16), -(CR19R20)nSC(=Y')R16, -(CR19R20)nSC(=Y')OR16, -(CR19R20)nSC(=Y')NR16R17, y R21; cada R11' es independientemente H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo, heterociclilo, arilo, o heteroarilo; R11, R12 y R13 son con independencia H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo, heterociclilo, arilo, o heteroarilo, o R11 y R12 junto con el nitrogeno al cual están unidos forman un anillo saturado, insaturado o aromático de 3-8 miembros que tiene 0-2 heteroátomos seleccionados entre O, S y N, donde dicho anillo está opcionalmente sustituido con uno o más grupos seleccionados entre halo, CN, CF3, -OCF3, -NO2, alquilo C1-6, -OH, -SH, -O(alquilo C1-6), -S(alquilo C1-6), -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)2, -SO2(alquilo C1-6), -CO2H, -CO2(alquilo C1-6), -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)2, -N(alquilo C1-6)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6, -NHSO2(alquilo C1-6), -N(alquilo C1-6)SO2(alquilo C1-6), -SO2NH2, -SO2NH(alquilo C1-6), -SO2N(alquilo C1-6)2, -OC(O)NH2, -OC(O)NH(alquilo C1-6), -OC(O)N(alquilo C1-6)2, -OC(O)O(alquilo C1-6), -NHC(C)NH(alquilo C1-6), -NHC(O)N(alquilo C1-6)2, -N(alquilo C1-6)C(O)NH(alquilo C1-6), -N(alquilo C1-6)C(O)N(alquilo C1-6)2, -NHC(O)NH(alquilo C1-6), -NHC(O)N(alquilo C1-6)2, -NHC(O)O(alquilo C1-6), y -N(alquilo C1-6)C(O)O(alquilo C1-6); R14 y R15 se seleccionan, con independencia, entre H, alquilo C1-12, arilo, carbociclilo, heterociclilo, y heteroarilo; W' es como el grupo de formulas (2); donde het es como se muestra en los restos de formulas (3); X2 es O, S, o NR9; R7 se selecciona entre H, halo, CN, CF3, -OCF3, -NO2, -(CR14R15)nC(=Y')R11, -(CR14R15)nC(=Y')OR11, -(CR14R15)nC(=Y')NR11R12, -(CR14R15)nNR11R12, -(CR14R15)nOR11, -(CR14R15)nSR11, -(CR14R15)nNR12C(=Y')R11, -(CR14R15)nNR12C(=Y')OR11, -(CR14R15)nNR13C(=Y')NR11R12, -(CR14R15)nNR12SO2R11, -(CR14R15)nOC(=Y')R11, -(CR14R15)nOC(=Y')OR11, -(CR14R15)nOC(=Y')NR11R12, -(CR14R15)nOS(O)2(OR11), -(CR14R15)nOP(=Y')(OR11)(OR12), -(CR14R15)nOP(OR11)(OR12), -(CR14R15)nS(O)R11, -(CR14R15)nS(O)2R11, -(CR14R15)nS(O)2NR11R12, -(CR14R15)nS(O)(OR11), -(CR14R15)nS(O)2(OR11), -(CR14R15)nSC(Y')R11, -(CR14R15)nSC(=Y')OR11, -(CR14R15)nSC(=Y')NR11R12, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo, heterociclilo, arilo, y heteroarilo; R8 se selecciona entre alquilo C1-12, arilo, carbociclilo, heterociclilo, y heteroarilo; R9 se selecciona entre H, -(CR14R15)nC(=Y')R11, -(CR14R15)nC(=Y')OR11, -(CR14R15)nC(=Y')NR11R12, -(CR14R15)qNR11R12, -(CR14R15)qOR11, -(CR14R15)qSR11, -(CR14R15)qNR12C(=Y')R11, -(CR14R15)qNR12C(=Y')OR11, -(CR14R15)qNR13C(=Y')NR11R12, -(CR14R15)qNR12SO2R11, -(CR14R15)qOC(=Y')R11, -(CR14R15)qOC(=Y')OR11, -(CR14R15)qOC(=Y')NR11R12, -(CR14R15)qOS(O)2(OR11), -(CR14R15)qOP(=Y')(OR11)(OR12), -(CR14R15)qOP(OR11)(OR12), -(CR14R15)nS(O)R11, -(CR14R15)nS(O)2R11, -(CR14R15)nS(O)2NR11R12, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo, heterociclilo, arilo, y heteroarilo; R10 es H, alquilo C1-6 o carbociclilo C3-4; X4 es como el resto de formula (4); R6 es H, halo, alquilo C1-6, alquenilo C2-8, alquinilo C2-8, carbociclilo, heteroarilo, heterociclilo, -OCF3, -NO2, -Si(alquilo C1-6), -(CR19R20)nNR16R17, -(CR19R20)nOR16, o -(CR19R20)n-SR16; R6' es H, halo, alquilo C1-6, carbociclilo, CF3, -OCF3, -NO2, -Si(alquilo C1-6), -(CR19R20)nNR16R17, -(CR19R20)nOR16, -(CR19R20)n-SR16, alquenilo C2-8, alquinilo C2-8, heterociclilo, arilo, o heteroarilo; p es 0, 1, 2 o 3; n es 0,1, 2 o 3; q es 2 o 3; donde cada uno de dicho alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo y heteroarilo de R1, R2, R3, R4, R5, R6, R6', R7, R8, R9, R10, R11, R11', R12, R13, R14, R15 y RA es independientemente opcionalmente sustituido con uno o más grupos seleccionados, con independencia, entre halo, CN, CF3, -OCF3, -NO2, oxo, -Si(alquilo C1-6), -(CR19R20)nC(=Y')R16, -(CR19R20)nC(=Y')OR16, -(CR19R20)nC(=Y')NR16R17, -(CR19R20)nNR16R17, -(CR19R20)nOR16, -(CR19R20)nSR16, -(CR19R20)nNR16C(=Y')R17, -(CR19R20)nNR16C(=Y')OR17, -(CR19R20)nNR18C(=Y')NR16R17, -(CR19R20)nNR17SO2R16, -(CR19R20)nOC(=Y')R16, -(CR19R20)OC(=Y')OR16, -(CR19R20)OC(=Y')NR16R17, -(CR19R20)nOS(O)2(OR16), -(CR19R20)nOP(=Y')(OR16)(OR17), -(CR19R20)nOP(OR16)(OR17), -(CR19R20)nS(O)R16, -(CR19R20)nS(O)2R16, -(CR19R20)nS(O)2NR16R17, -(CR19R20)nS(O)(OR16), -(CR19R20)nS(O)2(OR16), -(CR19R20)nSC(=Y')R16, -(CR19R20)nSC(=Y')OR16, -(CR19R20)nSC(=Y')NR16R17, y R21; cada R16, R17 y R18 es independientemente H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo, heterociclilo, arilo, o heteroarilo, donde dicho alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, o heteroarilo es opcionalmente sustituido con uno o más grupos seleccionados entre halo, CN, -OCF3, CF3, -NO2, alquilo C1-6, -OH, -SH, -O(alquilo C1-6), -S(alquilo C1-6), -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)2, -SO2(alquilo C1-6), -CO2H, -CO2(alquilo C1-6), -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)2, -N(alquilo C1-6)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHSO2(alquilo C1-6), -N(alquilo C1-6)SO2(alquilo C1-6), -SO2NH2, -SO2NH(alquilo C1-6), -SO2N(alquilo C1-6)2, -OC(O)NH2, -OC(O)NH(alquilo C1-6), -OC(O)N(alquilo C1-6)2, -OC(O)O(alquilo C1-6), -NHC(O)NH(alquilo C1-6), -NHC(O)N(alquilo C1-6)2, -N(alquilo C1-6)C(O)NH(alquilo C1-6), -N(alquilo C1-6)C(O)N(alquilo C1-6)2, -NHC(O)NH(alquilo C1-6), -NHC(O)N(alquilo C1-6)2, -NHC(O)O(alquilo C1-6), y -N(alquilo C1-6)C(O)O(alquilo C1-6); o R16 y R17 junto con el nitrogeno al cual están unidos forman un anillo saturado, insaturado o aromático de 3-8 miembros que tiene 0-2 heteroátomos seleccionados entre O, S y N, donde dicho anillo está opcionalmente sustituido con uno o más grupos seleccionados entre halo, CN, -OCF3, CF3, -NO2, alquilo C1-6, -OH, -SH, -O(alquilo C1-6), -S(alquilo C1-6), -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)2, -SO2(alquilo C1-6), -CO2H, -CO2(alquilo C1-6), -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)2, -N(alquilo C1-6)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHSO2(alquilo C1-6), -N(alquilo C1-6)SO2(alquilo C1-6), -SO2NH2, -SO2NH(alquilo C1-6), -SO2N(alquilo C1-6)2, -OC(O)NH2, -OC(O)NH(alquilo C1-6), -OC(O)N(alquilo C1-6)2, -OC(O)O(alquilo C1-6), -NHC(O)NH(alquilo C1-6), -NHC(O)N(alquilo C1-6)2, -N(alquilo C1-6)C(O)NH(alquilo C1-6), -N(alquilo C1-6)C(O)N(alquilo C1-6)2, -NHC(O)NH(alquilo C1-6), -NHC(O)N(alquilo C1-6)2, -NHC(O)O(alquilo C1-6), y -N(alquilo C1-6)C(O)O(alquilo C1-6); R19 y R20 se seleccionan, con independencia, entre H, alquilo C1-12, -(CH2)n-arilo, -(CH2)n-carbociclilo, -(CH2)n-heterociclilo, y -(CH2)n-heteroarilo; R21 es alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo, heterociclilo, arilo, o heteroarilo, donde cada miembro de R21 es opcionalmente sustituido con uno o más grupos seleccionados entre halo, oxo, CN, -OCF3, CF3, -NO2, alquilo C1-6, -OH, -SH, -O(alquilo C1-6), -S(alquilo C1-6), -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)2, -SO2(alquilo C1-6), -CO2H, -CO2(alquilo C1-6), -C(O)NH2, -C(O)NH(alquilo C1-6), -C(O)N(alquilo C1-6)2, -N(alquilo C1-6)C(O)(alquilo C1-6), -NHC(O)(alquilo C1-6), -NHSO2(alquilo C1-6), -N(alquilo C1-6)SO2(alquilo C1-6), -SO2NH2, -SO2NH(alquilo C1-6), -SO2N(alquilo C1-6)2, -OC(O)NH2, -OC(O)NH(alquilo C1-6), -OC(O)N(alquilo C1-6)2, -OC(O)O(alquilo C1-6), -NHC(O)NH(alquilo C1-6), -NHC(O)N(alquilo
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1512907P | 2007-12-19 | 2007-12-19 | |
US5401408P | 2008-05-16 | 2008-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069803A1 true AR069803A1 (es) | 2010-02-17 |
Family
ID=40350172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105524A AR069803A1 (es) | 2007-12-19 | 2008-12-18 | 5- anilinoimiazopiridinas y metodos de uso |
Country Status (28)
Country | Link |
---|---|
US (4) | US7923456B2 (es) |
EP (2) | EP2222675B1 (es) |
JP (1) | JP5421925B2 (es) |
KR (1) | KR101195329B1 (es) |
CN (1) | CN101945870B (es) |
AR (1) | AR069803A1 (es) |
AU (1) | AU2008343065B2 (es) |
BR (1) | BRPI0819529A2 (es) |
CA (1) | CA2706571C (es) |
CL (1) | CL2008003810A1 (es) |
CY (2) | CY1114663T1 (es) |
DK (2) | DK2222675T3 (es) |
ES (2) | ES2437141T3 (es) |
HK (2) | HK1188209A1 (es) |
HR (1) | HRP20151002T1 (es) |
HU (1) | HUE025192T2 (es) |
IL (1) | IL205977A (es) |
MX (1) | MX2010006800A (es) |
MY (1) | MY158829A (es) |
NZ (1) | NZ586802A (es) |
PE (2) | PE20131210A1 (es) |
PL (2) | PL2222675T3 (es) |
PT (2) | PT2222675E (es) |
RU (1) | RU2441004C1 (es) |
SI (2) | SI2222675T1 (es) |
TW (1) | TWI441820B (es) |
WO (1) | WO2009085983A1 (es) |
ZA (1) | ZA201003625B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009018657A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
EA201000948A1 (ru) | 2007-12-19 | 2011-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы вирусной полимеразы |
US8343977B2 (en) | 2009-12-30 | 2013-01-01 | Arqule, Inc. | Substituted triazolo-pyrimidine compounds |
WO2011082267A2 (en) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Substituted triazolo-pyrazine compounds |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
PE20190262A1 (es) | 2011-08-01 | 2019-02-25 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
KR101689946B1 (ko) | 2012-06-08 | 2016-12-26 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
BR112015022576A2 (pt) | 2013-03-14 | 2017-10-24 | Genentech Inc | produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
GB201321729D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR20220126813A (ko) | 2014-03-14 | 2022-09-16 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
CN116617401A (zh) | 2014-07-15 | 2023-08-22 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的组合物 |
CN108358939A (zh) * | 2014-07-29 | 2018-08-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途 |
EP3659621A1 (en) | 2014-09-13 | 2020-06-03 | Novartis AG | Combination therapies for cancer |
BR112017006664A2 (pt) | 2014-10-03 | 2017-12-26 | Novartis Ag | terapias de combinação |
US20170248603A1 (en) | 2014-10-06 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response |
US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
MA41338B1 (fr) * | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
PL3317301T3 (pl) | 2015-07-29 | 2021-11-15 | Novartis Ag | Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3 |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
RS63125B1 (sr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Antitela koja se specifično vezuju za pd-1 i njihova upotreba |
CN105399661A (zh) * | 2015-12-14 | 2016-03-16 | 华东师范大学 | 2,6-二溴甲基吡啶的制备方法 |
AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
WO2017180581A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
EP3458455B1 (en) | 2016-05-20 | 2021-06-16 | F. Hoffmann-La Roche AG | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
WO2018011100A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases |
WO2018011160A1 (en) * | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
JP7034133B2 (ja) * | 2016-07-14 | 2022-03-11 | エフ.ホフマン-ラ ロシュ アーゲー | 感染性疾患の処置のためのカルボキシ 6,7-ジヒドロ-4H-ピラゾロ[1,5-a]ピラジン化合物 |
EP3484886B1 (en) | 2016-07-14 | 2020-03-04 | Hoffmann-La Roche AG | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
WO2018036414A1 (zh) * | 2016-08-23 | 2018-03-01 | 北京诺诚健华医药科技有限公司 | 稠杂环类衍生物、其制备方法及其在医学上的应用 |
JP2020532982A (ja) | 2017-09-08 | 2020-11-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの診断及び治療方法 |
CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
WO2019224718A2 (en) | 2018-05-24 | 2019-11-28 | Janssen Biotech, Inc. | Psma binding agents and uses thereof |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
CN113473978A (zh) * | 2018-11-20 | 2021-10-01 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病氰基芳烃-苯胺化合物 |
MX2021007392A (es) | 2018-12-20 | 2021-08-24 | Novartis Ag | Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
AR118720A1 (es) | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
KR20220003023A (ko) * | 2019-04-30 | 2022-01-07 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 대해 활성인 신규 옥살릴 피페라진 |
AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
US20240059789A1 (en) | 2021-01-28 | 2024-02-22 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
WO2022169780A1 (en) | 2021-02-02 | 2022-08-11 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
WO2022195551A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarkers for cancer and methods of use thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU11248A1 (ru) | 1927-03-29 | 1929-09-30 | В.С. Григорьев | Способ очистки антрацена |
CA920592A (en) * | 1970-05-28 | 1973-02-06 | Denzel Theodor | Amino derivatives of pyrazolo-pyridine carboxylic acids and esters |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
WO1992018504A1 (fr) * | 1991-04-22 | 1992-10-29 | Otsuka Pharmaceutical Factory, Inc. | DERIVE DE PYRAZOLO[1,5-a]PYRIMIDINE ET AGENT ANTI-INFLAMMATOIRECONTENANT CE DERIVE |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
JPH08176070A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | ジデプシド誘導体及びpi3キナーゼ阻害剤 |
JPH08175990A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Pi3キナーゼ阻害剤とその製造法 |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
EP0961780B1 (en) | 1997-02-12 | 2007-04-11 | Electrophoretics Limited | Protein markers for lung cancer and use thereof |
CA2299355C (en) | 1997-08-08 | 2005-09-27 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
CZ20012498A3 (cs) * | 1999-01-13 | 2002-08-14 | Warner-Lambert Company | Benzoheterocyklické sloučeniny a jejich pouľití jako inhibitorů MEK |
PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
KR20020015376A (ko) | 1999-07-16 | 2002-02-27 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Mek 억제제를 사용한 만성 통증의 치료 방법 |
DK1676845T3 (da) | 1999-11-05 | 2008-09-15 | Astrazeneca Ab | Nye quinazolinderivater |
WO2001053298A1 (en) * | 2000-01-18 | 2001-07-26 | Neurogen Corporation | Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors |
ATE369359T1 (de) | 2000-02-15 | 2007-08-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
JP2001247477A (ja) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | 抗腫瘍剤 |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
JP2002020386A (ja) * | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
FR2811987A1 (fr) | 2000-07-18 | 2002-01-25 | Expansia Sa | Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium |
ATE374750T1 (de) | 2000-07-18 | 2007-10-15 | Dainippon Sumitomo Pharma Co | Serotoninwiederaufnahme-inhibitoren |
BRPI0112584B8 (pt) * | 2000-07-19 | 2021-05-25 | Warner Lambert Co | ésteres oxigenados de derivados de ácido benzidroxâmico de 4-iodofenilamino, composição farmacêutica e combinação |
WO2003018057A1 (fr) | 2001-07-26 | 2003-03-06 | Santen Pharmaceutical Co., Ltd. | Remede contre le glaucome contenant en tant qu'ingredient actif un compose presentant un effet inhibiteur de la kinase pi3 |
US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
US6894055B2 (en) | 2001-10-24 | 2005-05-17 | Iconix Pharmaceuticals Inc. | Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase |
US6908932B2 (en) | 2001-10-24 | 2005-06-21 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
CA2464924A1 (en) | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
AU2003245700A1 (en) | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
RU2300528C2 (ru) * | 2002-03-13 | 2007-06-10 | Эррэй Биофарма, Инк. | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек |
EP2130536B1 (en) | 2002-03-13 | 2013-05-08 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
MXPA05000453A (es) | 2002-07-10 | 2005-03-23 | Applied Research Systems | Derivados de benceno fusionados a azolidinona-vinilo. |
US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
EP1531813A1 (en) | 2002-07-10 | 2005-05-25 | Applied Research Systems ARS Holding N.V. | Use of compounds for increasing spermatozoa motility |
WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
MXPA05003058A (es) * | 2002-09-19 | 2005-05-27 | Schering Corp | Nuevas imidazopiridinas como inhibidores de cinasa dependientes de ciclina. |
SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
BRPI0416692A (pt) * | 2003-11-19 | 2007-01-30 | Array Biopharma Inc | inibidores heterocìclicos de mek e métodos de emprego destes |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
JP2008521858A (ja) * | 2004-12-01 | 2008-06-26 | ラボラトワール セローノ ソシエテ アノニム | 過増殖性疾患を処置するための[1,2,4]トリアゾロ[4,3−a]ピリジン誘導体 |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
TWI499420B (zh) | 2006-12-07 | 2015-09-11 | Hoffmann La Roche | 肌醇磷脂3-激酶抑制劑化合物及使用方法 |
JP5710268B2 (ja) * | 2007-12-19 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 8−アニリノイミダゾピリジン及びその抗ガン及び/又は抗炎症剤としての使用 |
-
2008
- 2008-12-18 EP EP08869100.1A patent/EP2222675B1/en active Active
- 2008-12-18 NZ NZ586802A patent/NZ586802A/en not_active IP Right Cessation
- 2008-12-18 ES ES08869100.1T patent/ES2437141T3/es active Active
- 2008-12-18 MX MX2010006800A patent/MX2010006800A/es active IP Right Grant
- 2008-12-18 BR BRPI0819529-3A patent/BRPI0819529A2/pt not_active IP Right Cessation
- 2008-12-18 DK DK08869100.1T patent/DK2222675T3/da active
- 2008-12-18 AR ARP080105524A patent/AR069803A1/es unknown
- 2008-12-18 PL PL08869100T patent/PL2222675T3/pl unknown
- 2008-12-18 DK DK13155995.7T patent/DK2690101T3/en active
- 2008-12-18 RU RU2010129826/04A patent/RU2441004C1/ru not_active IP Right Cessation
- 2008-12-18 ES ES13155995.7T patent/ES2546171T3/es active Active
- 2008-12-18 MY MYPI2010002814A patent/MY158829A/en unknown
- 2008-12-18 CA CA2706571A patent/CA2706571C/en not_active Expired - Fee Related
- 2008-12-18 JP JP2010539815A patent/JP5421925B2/ja active Active
- 2008-12-18 PL PL13155995T patent/PL2690101T3/pl unknown
- 2008-12-18 PT PT88691001T patent/PT2222675E/pt unknown
- 2008-12-18 PT PT131559957T patent/PT2690101E/pt unknown
- 2008-12-18 SI SI200831088T patent/SI2222675T1/sl unknown
- 2008-12-18 PE PE2013000381A patent/PE20131210A1/es not_active Application Discontinuation
- 2008-12-18 KR KR1020107015884A patent/KR101195329B1/ko not_active IP Right Cessation
- 2008-12-18 WO PCT/US2008/087482 patent/WO2009085983A1/en active Application Filing
- 2008-12-18 CL CL2008003810A patent/CL2008003810A1/es unknown
- 2008-12-18 PE PE2008002130A patent/PE20091158A1/es not_active Application Discontinuation
- 2008-12-18 TW TW097149416A patent/TWI441820B/zh not_active IP Right Cessation
- 2008-12-18 CN CN2008801270848A patent/CN101945870B/zh active Active
- 2008-12-18 HU HUE13155995A patent/HUE025192T2/en unknown
- 2008-12-18 EP EP13155995.7A patent/EP2690101B1/en active Active
- 2008-12-18 AU AU2008343065A patent/AU2008343065B2/en not_active Ceased
- 2008-12-18 SI SI200831490T patent/SI2690101T1/sl unknown
-
2009
- 2009-04-29 US US12/432,529 patent/US7923456B2/en active Active
-
2010
- 2010-05-21 ZA ZA2010/03625A patent/ZA201003625B/en unknown
- 2010-05-26 IL IL205977A patent/IL205977A/en not_active IP Right Cessation
-
2011
- 2011-02-10 HK HK14101128.7A patent/HK1188209A1/xx unknown
- 2011-02-10 HK HK11101302.8A patent/HK1147254A1/xx unknown
- 2011-03-07 US US13/041,735 patent/US8288408B2/en active Active
-
2012
- 2012-08-15 US US13/586,147 patent/US20120309765A1/en not_active Abandoned
-
2013
- 2013-02-05 US US13/759,850 patent/US9206174B2/en active Active
- 2013-11-21 CY CY20131101033T patent/CY1114663T1/el unknown
-
2015
- 2015-09-11 CY CY20151100786T patent/CY1116681T1/el unknown
- 2015-09-23 HR HRP20151002TT patent/HRP20151002T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069803A1 (es) | 5- anilinoimiazopiridinas y metodos de uso | |
AR062468A1 (es) | Compuestos de azabenzofuranil y metodos de uso | |
AR062469A1 (es) | Compuestos de azabenzotiofeno y azabenzofurano como inhibidores de la quinasa mek, una composicion farmaceutica que los comprende y el uso de estos en el tratamiento de trastornos inflamatorios e hiperproliferativos. | |
AR064031A1 (es) | Compuestos de azaindolilo y metodos de uso | |
AR060054A1 (es) | Inhibidores de c-met protein quinasas. composiciones farmaceuticas. | |
RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
AR075475A1 (es) | Derivados heterociclicos de piperazina utiles como agentes herbicidas y proceso para combatir el crecimiento de plantas indeseadas. | |
AR072657A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
AR072092A1 (es) | Diazacarbazoles y metodos de uso | |
AR041250A1 (es) | Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa | |
AR072537A1 (es) | Compuestos de piperazina con efecto herbicida | |
ECSP11011200A (es) | Derivados de oxadiazale como agonista de los receptores s1p1 | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
AR059246A1 (es) | Compuestos heterobiciclicos de tiofeno y metodos de uso | |
AR051195A1 (es) | Piridinas como inhibidores de plk | |
ES2567280T3 (es) | Métodos para preparar derivados de pirimidina útiles como inhibidores de proteína quinasa | |
AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
AR098853A1 (es) | Pirazoles sustituidos y usos de los mismos | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR061667A1 (es) | Arilamidas sustituidas con tetrazol | |
AR056688A1 (es) | Derivados de la 4- amino - quinazolina su preparacion y su aplicacion en terapeutica | |
ES2571028T3 (es) | Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso | |
AR073501A1 (es) | Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa | |
AR053728A1 (es) | Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |